Shop Vielight tech
Autism Clinical Results: Vielight itPBM Reduces ASD Severity and Parental Stress
This article is based on independent Autism research conducted with the Vielight Neuro Duo by Stanford University.
This article is for educational purposes only and summarizes a small, early-stage independent study. The Vielight Neuro Duo is a general wellness device. It is not intended to diagnose, treat, cure, or prevent autism spectrum disorder or any other condition, and it is not a substitute for evidence-based therapies.
At the moment, there is no answer for Autism Spectrum Disorder. There is a growing interest in non-pharmacological approaches, such as brain photobiomodulation.
This animation explores the results of an Autism Spectrum Disorder clinical study using the Vielight Neuro Duo, conducted by Dr Stefano Pallanti, a Stanford University Professor and Director of Istituto di Neuroscienze, Florence, Italy.
Introduction to the Study
Data was reported and analyzed from 21 patients, 13 males and 8 females with an average age of 9.1. The age range is 5 to 15 years old.
The study was conducted over six months at home.
Participants used the Vielight Neuro Duo with its two protocols, the Alpha 10 hertz protocol and the Gamma 40 hertz protocol.
Both Alpha and Gamma protocols were administered each day, one in the morning and one in the evening. Each session had a duration of 20 min, during which children were involved in stimulating activities, such drawing, coloring, reading, playing games, or doing homework.
Key Results
Findings show that after 6 months, transcranial-intranasal brain PBM was associated with:
- reduction in ASD severity, as shown by a decrease in CARS scores (p < 0.001).
- reduction in noncompliant behavior
- reduction in parental stress
- reduction in behavioral and cognitive rigidity
- improvement in attentional functions and in sleep quality.
Secondary Benefits
These improvements not only enhanced the lives of the patients but also greatly reduced stress among their parents, as measured by the SDAG scale, creating a more peaceful and effective environment for growth.
What the study reported
After six months, the researchers reported that itPBM use was associated with the following observed changes (as measured or rated within the study):
- A decrease in ASD-severity scores on the CARS scale (within-group change, p < 0.001).
- Lower levels of noncompliant behavior.
- Reduced parental stress, as measured on the SDAG scale.
- Reduced behavioral and cognitive rigidity.
- Improvements in reported attention and sleep quality.
Note on the statistic: the p < 0.001 figure reflects a before-and-after comparison within the same group, not a comparison against an untreated control. It indicates the scores moved over time; it does not, on its own, establish what caused the change.
The proposed mechanism (a hypothesis, not a conclusion)
The researchers’ working idea is that the device targets the Default Mode Network (DMN), a set of connected brain regions. Differences in DMN connectivity have been observed in autism, and some researchers hypothesize these differences may relate to challenges in social communication and to repetitive behaviors. The two protocols are proposed to act differently: the Alpha (10 Hz) mode is associated with relaxation, and the Gamma (40 Hz) mode with attention and cognitive engagement.
It’s important to be clear that this is a proposed explanation for why an effect might occur — it is not itself evidence that the effect is real or that the device changes the DMN in children with ASD. The study authors note that neuroimaging and further research are needed to investigate these underlying questions.
Safety
Within this study, the approach was reported as well-tolerated, with minimal side effects noted. As with any intervention, families should discuss safety and suitability with a qualified healthcare professional, particularly for a child.
What comes next
The honest summary is that this is a small, uncontrolled, early-stage study with promising-looking but preliminary results. The meaningful next step — which the authors themselves call for — is a larger randomized, controlled, ideally blinded trial that can separate a genuine device effect from expectation. Until that exists, itPBM should be understood as an area of ongoing research interest in neurodevelopmental conditions, not an established option for autism.
